Beam Therapeutics, Inc.(BEAM)_个股概要_股票价格_最新资讯_行情走势_历史数据

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

BEAM Beam Therapeutics, Inc.

美国独立日休市 07-03 13:00:00 EDT

20.01

+0.13

+0.65%

盘后20.28

+0.27+1.35%

16:51 EDT

最高20.46	最低19.57	成交量136.47万
今开20.20	昨收19.88	日振幅4.47%
总市值20.12亿	流通市值18.21亿	总股本1.01亿
成交额2,721万	换手率1.50%	流通股本9,103万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"BEAM","market":"US","secType":"STK","nameCN":"Beam Therapeutics, Inc.","latestPrice":20.01,"timestamp":1751562000000,"preClose":19.88,"halted":0,"volume":1364708,"hourTrading":{"tag":"盘后","latestPrice":20.28,"preClose":20.01,"latestTime":"16:51 EDT","volume":9146,"amount":183026.5645,"timestamp":1751575912068},"delay":0,"floatShares":91026800,"shares":100557094,"eps":-4.58,"marketStatus":"美国独立日休市","change":0.13,"latestTime":"07-03 13:00:00 EDT","open":20.2,"high":20.4583,"low":19.57,"amount":27206851.440992,"amplitude":0.044683,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-4.58,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1751875200000},"marketStatusCode":7,"adr":0,"listingDate":1580965200000,"exchange":"NASDAQ","adjPreClose":19.88,"preHourTrading":{"tag":"盘前","latestPrice":20.16,"preClose":19.88,"latestTime":"09:29 EDT","volume":16564,"amount":340978.271692,"timestamp":1751549361070},"postHourTrading":{"tag":"盘后","latestPrice":20.28,"preClose":20.01,"latestTime":"16:51 EDT","volume":9146,"amount":183026.5645,"timestamp":1751575912068},"volumeRatio":0.9814462380474048,"impliedVol":0.35,"impliedVolPercentile":0.04},"requestUrl":"/m/hq/s/BEAM/tweets","defaultTab":"tweets","newsList":[{"id":"2548446380","title":"Chief Medical Officer Simon Amy Reports Disposal of Common Shares of Beam Therapeutics Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2548446380","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548446380?lang=zh_cn&edition=full","pubTime":"2025-07-04 05:30","pubTimestamp":1751578241,"startTime":"0","endTime":"0","summary":"Amy Simon, the Chief Medical Officer of Beam Therapeutics Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Beam Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on July 03, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"首席医疗官Simon Amy报告Beam Therapeutics Inc普通股处置情况","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250703:nNDLbZfzMn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","BK4139","BK4611","BEAM","BK4505","BK4588","BK4556","BK4585"],"gpt_icon":0},{"id":"2548380922","title":"Beam Therapeutics Acquires Early-Stage Life Sciences Firm","url":"https://stock-news.laohu8.com/highlight/detail?id=2548380922","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548380922?lang=zh_cn&edition=full","pubTime":"2025-07-04 05:04","pubTimestamp":1751576662,"startTime":"0","endTime":"0","summary":"Beam Therapeutics ( ($BEAM) ) has provided an update. On July 1, 2025, Beam Therapeutics Inc. acquired an early-stage life sciences company, agreei...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/beam-therapeutics-acquires-early-stage-life-sciences-firm?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"Beam Therapeutics收购早期生命科学公司","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/beam-therapeutics-acquires-early-stage-life-sciences-firm?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4535","BK4139","BK4611","BEAM","SSI","BK4505","BK4588","BK4539","BK4007","BK4556","BK4585"],"gpt_icon":0},{"id":"2548038778","title":"BRIEF-Beam Therapeutics Buys Early-Stage Life Sciences Company","url":"https://stock-news.laohu8.com/highlight/detail?id=2548038778","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548038778?lang=zh_cn&edition=full","pubTime":"2025-07-04 04:42","pubTimestamp":1751575341,"startTime":"0","endTime":"0","summary":"BRIEF-Beam Therapeutics Buys Early-Stage Life Sciences CompanyJuly 3  - Beam Therapeutics Inc BEAM.O:BEAM THERAPEUTICS INC - BUYS EARLY-STAGE LIFE SCIENCES COMPANY - SEC FILINGBEAM THERAPEUTICS INC - POTENTIAL ADDITIONAL PAYMENTS UP TO $89 MILLION - SEC FILINGBEAM THERAPEUTICS INC - MAXIMUM OF 5.2 MILLION MILESTONE SHARES ISSUABLE AT $17.01 PER SHARE - SEC FILINGFurther company coverage: BEAM.O ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"BRIEF-Beam Therapeutics收购早期生命科学公司","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250703:nFWN3T00MI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","BK4139","BK4611","BEAM","BK4505","BK4588","BK4556","BK4585"],"gpt_icon":0},{"id":"2548387149","title":"Beam Therapeutics Inc - Potential Additional Payments up to $89 Mln - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2548387149","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548387149?lang=zh_cn&edition=full","pubTime":"2025-07-04 04:34","pubTimestamp":1751574883,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"Beam Therapeutics Inc-潜在额外付款高达8900万美元-SEC备案","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250703:nFWN3T00MI:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BEAM","BK4611","BK4585","BK4535","BK4588","BK4505","BK4556","BK4139"],"gpt_icon":0},{"id":"2548387145","title":"Beam Therapeutics Inc - Buys Early-Stage Life Sciences Company - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2548387145","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548387145?lang=zh_cn&edition=full","pubTime":"2025-07-04 04:34","pubTimestamp":1751574883,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"Beam Therapeutics Inc-收购早期生命科学公司-向SEC提交文件","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250703:nFWN3T00MI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BEAM","BK4556","BK4139","BK4535","BK4588","BK4585","BK4611","BK4505"],"gpt_icon":0},{"id":"2548879023","title":"Beam Therapeutics Inc. Issues 403,128 Shares as Upfront Payment and Announces Potential Additional Milestone Shares Worth Up to $89 Million in Acquisition Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2548879023","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548879023?lang=zh_cn&edition=full","pubTime":"2025-07-04 04:30","pubTimestamp":1751574659,"startTime":"0","endTime":"0","summary":"Beam Therapeutics Inc. Issues 403,128 Shares as Upfront Payment and Announces Potential Additional Milestone Shares Worth Up to $89 Million in Acquisition Deal. On July 1, 2025, Beam Therapeutics Inc. acquired an early-stage life sciences company, issuing 403,128 shares of its common stock as an upfront payment. Additionally, Beam Therapeutics agreed to potential milestone payments up to $89,000,000, either in cash or shares, based on certain milestones. Based on a closing price of $17.01 per share on June 30, 2025, the maximum potential shares for milestone payments could be 5,232,216, although the exact number remains undetermined. These transactions were unregistered under the Securities Act of 1933.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"Beam Therapeutics Inc.发行403,128股股票作为预付款，并宣布在收购交易中可能额外发行价值高达8900万美元的里程碑股票","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250703:nNDL3qthyc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BEAM","BK4535","BK4588","BK4611","BK4556","BK4139","BK4505","BK4585"],"gpt_icon":0},{"id":"2543606040","title":"Beam Therapeutics (BEAM) Gets a Buy from Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2543606040","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2543606040?lang=zh_cn&edition=full","pubTime":"2025-06-16 22:55","pubTimestamp":1750085720,"startTime":"0","endTime":"0","summary":"Wedbush analyst David Nierengarten maintained a Buy rating on Beam Therapeutics (BEAM – Research Report) today and set a price target of $57.00. Th...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/beam-therapeutics-beam-gets-a-buy-from-wedbush-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"Beam Therapeutics(BEAM)获得Wedbush收购","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/beam-therapeutics-beam-gets-a-buy-from-wedbush-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4535","BK4139","BEAM","BK4556","BK4505","BK4585","BK4611","BK4588"],"gpt_icon":0},{"id":"2543678450","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: Merus (MRUS) and Beam Therapeutics (BEAM)","url":"https://stock-news.laohu8.com/highlight/detail?id=2543678450","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2543678450?lang=zh_cn&edition=full","pubTime":"2025-06-16 17:40","pubTimestamp":1750066806,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Merus (MRUS – Research Report) and Beam Therapeuti...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-merus-mrus-and-beam-therapeutics-beam-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"分析师对这些医疗保健公司的看法相互矛盾：Merus(MRUS)和Beam Therapeutics(BEAM)","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-merus-mrus-and-beam-therapeutics-beam-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4137","BK4139","BK4556","BK4588","BK4505","BK4585","BK4611","LU0109394709.USD","BEAM","LU0889565916.HKD","MRUS","BK4535","HCSG","LU0320765992.SGD"],"gpt_icon":0},{"id":"2543801216","title":"Beam Therapeutics’ BEAM-101: Promising Advancements in Sickle Cell Disease Treatment with Strong Phase 1/2 Trial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2543801216","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2543801216?lang=zh_cn&edition=full","pubTime":"2025-06-13 21:35","pubTimestamp":1749821715,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Patrick Trucchio has reiterated their bullish stance on BEAM stock, giving a Buy rating on June 5. Patrick Trucchio has giv...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/beam-therapeutics-beam-101-promising-advancements-in-sickle-cell-disease-treatment-with-strong-phase-1-2-trial-results-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"Beam Therapeutics的BEAM-101：镰状细胞病治疗取得有希望的进展，1/2期试验结果强劲","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/beam-therapeutics-beam-101-promising-advancements-in-sickle-cell-disease-treatment-with-strong-phase-1-2-trial-results-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4535","BK4505","BEAM","BK4585","BK4139","BK4588","BK4611","BK4556"],"gpt_icon":0},{"id":"2543068641","title":"Beam Therapeutics Announces Promising New Data from BEACON Phase 1/2 Trial of BEAM-101 for Sickle Cell Disease at EHA 2025 Congress","url":"https://stock-news.laohu8.com/highlight/detail?id=2543068641","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2543068641?lang=zh_cn&edition=full","pubTime":"2025-06-13 19:00","pubTimestamp":1749812416,"startTime":"0","endTime":"0","summary":"Beam Therapeutics Announces Promising New Data from BEACON Phase 1/2 Trial of BEAM-101 for Sickle Cell Disease at EHA 2025 Congress. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Beam Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on June 13, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"Beam Therapeutics在EHA 2025大会上宣布了BEAM-101治疗镰状细胞病的BEACON 1/2期试验的有希望的新数据","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250613:nNDL1Sx34V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","BK4611","BK4535","IE00B3QW5Z07.USD","BK4585","IE00BKPKM429.USD","BEAM","BK4112","LU2210149790.SGD","IE00BGHQF748.EUR","NDAQ","LU2095319765.USD","IE00B64PRP62.GBP","BK4588","BK4556","LU2210150020.SGD","BK4139"],"gpt_icon":0},{"id":"2543864936","title":"Beam Therapeutics Inc - Enrollment Complete in Beacon Trial, 30 Patients Expected by Mid-2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2543864936","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2543864936?lang=zh_cn&edition=full","pubTime":"2025-06-13 19:00","pubTimestamp":1749812400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"Beam Therapeutics Inc-BEACON试验招募完成，预计到2025年中期将有30名患者","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250613:nTUABHWY9D:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BEAM","BK4585","BK4556","BK4611","BK4588","BK4535","BK4505","BK4139"],"gpt_icon":0},{"id":"2543686948","title":"Beam Therapeutics Announces New Data From Beacon Phase 1/2 Clinical  Trial of Beam-101 Supporting Differentiated Profile in Sickle Cell Disease (Scd) at European Hematology Association (Eha) 2025 Congress","url":"https://stock-news.laohu8.com/highlight/detail?id=2543686948","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2543686948?lang=zh_cn&edition=full","pubTime":"2025-06-13 19:00","pubTimestamp":1749812400,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"Beam Therapeutics在欧洲血液学协会(Eha)2025年大会上宣布Beam-101支持镰状细胞病(Scd)分化特征的BEACON 1/2期临床试验的新数据","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250613:nTUABHWY9D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BEAM","BK4588","BK4611","BK4585","BK4535","BK4505","BK4556"],"gpt_icon":0},{"id":"1195291286","title":"Cathie Wood继续抛售Palantir，增持Beam Therapeutics和GitLab","url":"https://stock-news.laohu8.com/highlight/detail?id=1195291286","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1195291286?lang=zh_cn&edition=full","pubTime":"2025-06-12 14:40","pubTimestamp":1749710400,"startTime":"0","endTime":"0","summary":"周三，Cathie Wood 的 Ark Invest 进行了多项重要交易，其中最引人注目的包括以下几家公司： $Beam Therapeutics, Inc.$ 、 $GitLab, Inc.$ 、 $Palantir Technologies Inc.$ 、 $Roblox Corporation$ 、 $克瑞拓斯安全防卫$ 、Cloudflare、 $CrowdStrike Holdings, Inc.$ 、 $CoreWeave, Inc.$ 和 $AvidXchange Holdings, Inc$ 。关于 $Beam Therapeutics, Inc.$ 的交易：Ark Invest 旗下的 ARK Innovation ETF买入了 349,264 股 Beam Therapeutics。关于 $Palantir Technologies Inc.$ 的交易：与买入 BEAM 和 GTLB 不同，Ark Invest 选择减持 $Palantir Technologies Inc.$ 的股票，减持行为发生在旗下的多个 ETF 中，包括 ARKK、ARK Autonomo","market":"us","thumbnail":"https://static.tigerbbs.com/0fb0479ff67cd3a760cdce353bcb60ed","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/0fb0479ff67cd3a760cdce353bcb60ed"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"31d054bcd0cb132ff65472312c604202","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GTLB","PLTR","BEAM"],"gpt_icon":1},{"id":"2541895894","title":"Beam Therapeutics Confirms Key Decisions at Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2541895894","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541895894?lang=zh_cn&edition=full","pubTime":"2025-06-07 04:45","pubTimestamp":1749242749,"startTime":"0","endTime":"0","summary":"Beam Therapeutics ( ($BEAM) ) has provided an announcement. On June 4, 2025, Beam Therapeutics held its annual meeting of stockholders, where key d...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/beam-therapeutics-confirms-key-decisions-at-annual-meeting?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"Beam Therapeutics在年会上确认关键决策","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/beam-therapeutics-confirms-key-decisions-at-annual-meeting?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BEAM","BK4505","BK4535","BK4556","BK4588","BK4539","BK4611","LENZ","BK4139","BK4007","BK4585"],"gpt_icon":0},{"id":"2541077159","title":"Bernstein Reaffirms Their Buy Rating on Beam Therapeutics (BEAM)","url":"https://stock-news.laohu8.com/highlight/detail?id=2541077159","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541077159?lang=zh_cn&edition=full","pubTime":"2025-06-06 00:55","pubTimestamp":1749142524,"startTime":"0","endTime":"0","summary":"In a report released today, William Pickering from Bernstein maintained a Buy rating on Beam Therapeutics (BEAM – Research Report), with a price ta...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/bernstein-reaffirms-their-buy-rating-on-beam-therapeutics-beam-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"伯恩斯坦重申对Beam Therapeutics(BEAM)的买入评级","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/bernstein-reaffirms-their-buy-rating-on-beam-therapeutics-beam-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BEAM"],"gpt_icon":0},{"id":"2541737093","title":"BEAM Up on FDA's Orphan Drug Status for Gene-Editing Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2541737093","media":"Zacks","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541737093?lang=zh_cn&edition=full","pubTime":"2025-06-04 22:58","pubTimestamp":1749049080,"startTime":"0","endTime":"0","summary":"Beam TherapeuticsBEAM announced that the FDA has granted an orphan drug designation to its investigational genome-editing candidate, BEAM-101, for the treatment of sickle cell disease , an inherited blood disorder.The FDA grants orphan drug designation to support the development of medicines for rare disorders that affect fewer than 200,000 people in the United States. The designation makes the sponsor eligible to receive seven years of market exclusivity following a potential approval, along with the exemption of FDA application fees and tax credits for qualified clinical studies.Shares of Beam Therapeutics were up 4.3% yesterday following the announcement of the news.However, the stock has plunged 32% so far this year compared with the industry’s decline of 2.9%.In December 2024, the company announced new safety and efficacy data from the BEACON study evaluating BEAM-101 in SCD patients with severe vaso-occlusive crises.The data showed that treatment with BEAM-101 led to a robust and","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"提高FDA基因编辑疗法的孤儿药地位","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/beam-fdas-orphan-drug-status-145800778.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0234570918.USD","IE0009355771.USD","LU1035775433.USD","CRSP","LU1430594728.SGD","LU0061475181.USD","LU0320765992.SGD","IE00BZ9MQY76.HKD","IE00B894F039.SGD","LU0889565916.HKD","BK4567","BK4585","LU0079474960.USD","SCD","IE00BJJMRZ35.SGD","BK4611","IE00B2B36J28.USD","LU1093756168.USD","IE00B19Z3B42.SGD","LU1778281490.HKD","NTLA","LU0109394709.USD","LU2456880835.USD","VRTX","LU0058720904.USD","SG9999013999.USD","LU1093756325.SGD","LU2362541513.USD","LU2362541273.HKD","LU1861558580.USD","BK4505","BK4139","LU0417517546.SGD","SG9999001176.SGD","SG9999001176.USD","IE00B19Z3581.USD","SGXZ57979304.SGD","IE00BFTCPJ56.SGD","IE00B19Z9P08.USD","LU2236285917.USD","LU2362540622.SGD","BEAM","LU1585245621.USD","LU2324357040.USD","BK4533","LU2237438978.USD","BK4588","IE0002270589.USD","BK4535","LU2462157665.USD"],"gpt_icon":0},{"id":"2541093732","title":"Can CRISPR Build on Casgevy's Success With Its In Vivo Pipeline?","url":"https://stock-news.laohu8.com/highlight/detail?id=2541093732","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541093732?lang=zh_cn&edition=full","pubTime":"2025-06-04 20:55","pubTimestamp":1749041700,"startTime":"0","endTime":"0","summary":"CRISPR Therapeutics is currently evaluating two in vivo candidates, namely CTX310 and CTX320, in separate early-stage studies, targeting ANGPTL3 and lipoprotein [Lp], respectively — both associated with atherosclerotic heart disease.Last month, CRSP reported initial top-line data from the first 10 patients acrossthe first four cohorts of the phase I study on CTX310. A single dose demonstrated dose-dependent decreases in low-density lipoprotein  and triglyceride  levels, with peak reduction of up to 82% in TG and up to 81% in LDL.These results have raised excitement around CTX320, a readout from which is expected later in the second quarter of 2025. CRISPR Therapeutics also intends to advance two additional in vivo programs into the clinic by year-end, further expanding its footprint in this emerging modality.The company is currently lagging behind Intellia TherapeuticsNTLA, which is one of the few companies with multiple clinical-stage in vivo gene editing programs. Intellia is advanci","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"CRISPR能否在Casgevy体内管线成功的基础上再接再厉？","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/crispr-build-casgevys-success-vivo-125500765.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BGSX","CRSP","BK4153","BK4585","HAE","TG","LU1169590202.USD","BK4611","LU1169589451.USD","LU1861558580.USD","BK4090","BK4556","LU0106261612.USD","LDL","IE00BLDYK493.USD","LU0205194284.USD","NTLA","BEAM","IE00B64QTZ34.USD","BK4588","BK4505","LU0012050646.USD","BK4198","LU1861559042.SGD","BK4139","BK4535","LU0205193047.USD"],"gpt_icon":0},{"id":"2540709879","title":"BUZZ-U.S. STOCKS ON THE MOVE-Guardant Health, Hewlett Packard Enterprise, Venture Global","url":"https://stock-news.laohu8.com/highlight/detail?id=2540709879","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540709879?lang=zh_cn&edition=full","pubTime":"2025-06-04 01:42","pubTimestamp":1748972559,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Guardant Health, Hewlett Packard Enterprise, Venture GlobalEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morn","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"嗡嗡声-美国。股票动态-Guardant Health、慧与、Venture Global","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250603:nL6N3S60GT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CVX","LIF","FDX","STR","LU1064131342.USD","PINS","DVN","AGEN","BMBL","LU2125154778.USD","LU2290526834.HKD","IE00BGHQF524.EUR","NEM","VG","LU1988902786.USD","SCCO","HPE","IE00BD4GTW91.USD","KYMR","OSK","DG","WWD","LU1978683503.SGD","LU1951198990.SGD","XYZ","BEAM","GH","SG9999001143.SGD","SIG","FCX","LU0985489474.SGD","ANRO","LU2286300806.USD","STRK","BK4015","LU2211817866.USD","XOM"],"gpt_icon":1},{"id":"2540077442","title":"嗡嗡声--美国股票走势-Hims & Hers Health、Microstrategy、联邦快递","url":"https://stock-news.laohu8.com/highlight/detail?id=2540077442","media":"路透中文","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540077442?lang=zh_cn&edition=full","pubTime":"2025-06-03 21:12","pubTimestamp":1748956377,"startTime":"0","endTime":"0","summary":"由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250603:nL3S3S610Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BHP.AU","LU0345780521.USD","GEV","BK4161","IE00BZ18W456.USD","LU0266512127.USD","LU2294711713.HKD","RIO.UK","BX","AU","PINS","FANG","LU0124384867.USD","BK4551","OSK","VNOM","DG","NEM","IE00BGHQF524.EUR","ANRO","SCCO","CEG","HIMS","RIO.AU","STR","XYZ","MSTR","FCX","IE00BZ9MQY76.HKD","IE00BLSP4452.SGD","LU0300736062.USD","LU2237438978.USD","LU0498741890.SGD","FDX","KYMR","BK4081","AGEN","UUUU","BEAM","SIG","BK4213","BMBL","LU0300736492.USD","STRK","WWD","LU0171293334.USD"],"gpt_icon":1},{"id":"2540803826","title":"Roadzen’s DrivebuddyAI Awarded Patent for Real-Time Driver Drowsiness Detection — Crosses 1.8 Billion Kilometers of Real-World AI Driving Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2540803826","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540803826?lang=zh_cn&edition=full","pubTime":"2025-06-03 21:01","pubTimestamp":1748955660,"startTime":"0","endTime":"0","summary":"New Patent Positions DrivebuddyAI to Lead India’s Upcoming Road Safety Mandates, Achieves 72% Accident Reduction Across Fleets. NEW YORK, June 03, 2025  -- Roadzen Inc.  , a global leader in AI at the intersection of insurance and mobility, today announced that its DrivebuddyAI platform has been granted a patent in India for its Real-Time Driver Drowsiness Detection Algorithm.DrivebuddyAI’s patented system leverages AI and computer vision to monitor over 92 real-time eye and facial cues, enabling early detection of driver fatigue and triggering instant alerts—helping prevent accidents before they occur. The newly granted patent strengthens Roadzen’s expanding global IP portfolio, with additional filings underway in the U.S. and Europe.According to the U.S. National Highway Traffic Safety Administration , crashes involving at least one distracted driver accounted for 29% of all motor vehicle crashes and costs. This underscores the urgent need for real-time safety technologies like Drive","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"Roadzen的DrivebuddyAI获得实时驾驶员睡意检测专利——跨越18亿公里真实世界AI驾驶数据","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/roadzen-drivebuddyai-awarded-patent-real-130100836.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ARAI","BK4139","RDZNW","BEAM","BK4556","CARD","BK4535","BK4131","BK4505","BK4585","BK4611","BK4588"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.beamtx.com","stockEarnings":[{"period":"1week","weight":0.1674},{"period":"1month","weight":0.1854},{"period":"3month","weight":0.3104},{"period":"6month","weight":-0.2116},{"period":"1year","weight":-0.1478},{"period":"ytd","weight":-0.1931}],"compareEarnings":[{"period":"1week","weight":0.022},{"period":"1month","weight":0.0491},{"period":"3month","weight":0.2376},{"period":"6month","weight":0.0564},{"period":"1year","weight":0.134},{"period":"ytd","weight":0.067}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Beam Therapeutics Inc.成立于2017年1月25日，是一家生物技术公司，致力于根据其专有的碱基编辑技术创建一类新型的精密基因药物，其愿景是为患有严重疾病的患者提供终身治疗疾病。","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.020436},{"month":2,"riseRate":0.6,"avgChangeRate":0.123426},{"month":3,"riseRate":0,"avgChangeRate":-0.205206},{"month":4,"riseRate":0.5,"avgChangeRate":-0.128126},{"month":5,"riseRate":0.5,"avgChangeRate":0.074807},{"month":6,"riseRate":0.833333,"avgChangeRate":0.150103},{"month":7,"riseRate":0.5,"avgChangeRate":0.087674},{"month":8,"riseRate":0.4,"avgChangeRate":-0.006987},{"month":9,"riseRate":0.2,"avgChangeRate":-0.081345},{"month":10,"riseRate":0.4,"avgChangeRate":0.021253},{"month":11,"riseRate":0.8,"avgChangeRate":0.196147},{"month":12,"riseRate":0.4,"avgChangeRate":0.072364}],"exchange":"NASDAQ","name":"Beam Therapeutics, Inc.","nameEN":"Beam Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.2","shortVersion":"4.34.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Beam Therapeutics, Inc.(BEAM)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Beam Therapeutics, Inc.(BEAM)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Beam Therapeutics, Inc.,BEAM,Beam Therapeutics, Inc.股票,Beam Therapeutics, Inc.股票老虎,Beam Therapeutics, Inc.股票老虎国际,Beam Therapeutics, Inc.行情,Beam Therapeutics, Inc.股票行情,Beam Therapeutics, Inc.股价,Beam Therapeutics, Inc.股市,Beam Therapeutics, Inc.股票价格,Beam Therapeutics, Inc.股票交易,Beam Therapeutics, Inc.股票购买,Beam Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Beam Therapeutics, Inc.(BEAM)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Beam Therapeutics, Inc.(BEAM)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}

公司概况